ArticleCHEST pulmonary2026
Chronic Pulmonary Complications After COVID-19: An Observational Study of Postinfection Lung Changes Over 2 Years.
Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term pulmonary complications after COVID-19 are increasingly recognized, but few studies have characterized their progression and risk factors over extended follow-up. Research Question: What are the prevalence, progression, and predictors of chronic pulmonary complications in COVID-19 survivors over a 24-month period? Study Design and Methods: We conducted a prospective observational cohort study of 355 adults (20-55 years of age) with polymerase chain reaction-confirmed COVID-19 in Egypt, followed at 6, 12, and 24 months after infection. Assessments included pulmonary function tests, high-resolution CT scan, and standardized symptom questionnaires. Multivariable logistic regression was used to identify independent predictors of interstitial fibrosis and pulmonary embolism (PE). Results: Chronic cough prevalence decreased from 45% at 6 months to 7% at 24 months ( Interpretation: Most COVID-19 survivors experienced symptomatic and functional improvement over 2 years. However, a substantial subset, particularly those unvaccinated or with severe initial illness, developed progressive interstitial fibrosis and increased risk of PE. Long-term pulmonary surveillance and vaccination may reduce these chronic sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.